Simple Summary Breast cancer is the most common cancer among women. It is estimated
that 2.3 million new cases of BC are diagnosed globally each year. Based on mRNA gene …

Breast cancer is a genetically and clinically heterogeneous disease with multiple subtypes.
The classification of these subtypes has evolved over the years. The most common and …

Background AKT pathway activation is implicated in endocrine-therapy resistance. Data on
the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy …

Background In an interim analysis of this phase 3 trial, the addition of pembrolizumab to
chemotherapy resulted in longer progression-free survival than chemotherapy alone among …

PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal
growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis …

Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …

Background Adjuvant abemaciclib plus endocrine therapy previously showed a significant
improvement in invasive disease-free survival and distant relapse-free survival in hormone …

Background The recurrence score based on the 21-gene breast-cancer assay has been
clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human …

Background Pembrolizumab monotherapy showed durable antitumour activity and
manageable safety in patients with metastatic triple-negative breast cancer. We aimed to …

Abstract Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in
breast cancer, has limited value for treatment decisions due to questionable analytical …